Stephen Robert Gregory

Stephen Robert Gregory discloses dealings in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) to SEDI. Over a trading history stretching from 19 August 2016 to 27 November 2017, the count stands at 11 filings.

Every open-market trade on record is a purchase: 11 purchases worth €130k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2017: 10 purchases and no sales on the market.

In size, the median ticket on the buying side is €7,706. No cluster: in 11 purchases, no other insider of the company bought within 30 days.

The newest entry dates from 1 December 2017: an open-market purchase of €2,124, in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). The median gap between a trade and its publication by SEDI is 4 days. This delay matters because a trade only becomes useful information once it is public. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.